| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT04886986 Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic… |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-12 | NCT04886986 Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic… |
Enrollment increased: 20 -> 42 participants |
| 2026-05-23 | NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC |
date change Primary completion pushed: 2026-06-30 -> 2026-11-30 |
| 2026-05-23 | NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC |
date change Completion pushed: 2027-06-30 -> 2027-11-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive… | Prostatic Neoplasms | Active, Not Recruiting |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing… | Prostatic Neoplasms | Active, Not Recruiting |
| Phase 2 | |||
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment… | Prostate Carcinoma | Recruiting |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT06526299 | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With… | Metastatic Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Recruiting |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer | Metastatic Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT06964958 | 177LuPSMA in Renal Cell Carcinoma | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate… | Prostate Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT07219147 | 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic… | Metastatic Castration-Resistant Prostate Adenocarcinoma | Recruiting |
| NCT07145177 | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate… | Metastatic Prostate Cancer | Recruiting |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | Glioma | Recruiting |
| NCT05818683 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic… | Metastatic Castration-resistant Prostate Neoplasms | Recruiting |
| NCT06095089 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | Prostatic Neoplasms | Recruiting |
| NCT04886986 | Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic… | Prostate Cancer | Recruiting |
| NCT05079698 | A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of… | Prostate Cancer | Active, Not Recruiting |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant… | Prostate Cancer | Active, Not Recruiting |